Astrazeneca Plc Stock Net Asset
| AZN Stock | 10,474 412.00 4.09% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca | Net Asset |
AstraZeneca PLC Company Net Asset Analysis
AstraZeneca PLC's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current AstraZeneca PLC Net Asset | 101.12 B |
Most of AstraZeneca PLC's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
AstraZeneca Total Assets
Total Assets |
|
Based on the recorded statements, AstraZeneca PLC has a Net Asset of 101.12 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United Kingdom stocks is notably lower than that of the firm.
AstraZeneca Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in net asset category among its peers.
AstraZeneca PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AstraZeneca PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AstraZeneca PLC's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
AstraZeneca Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 183.54 B | ||||
| Shares Outstanding | 1.55 B | ||||
| Shares Owned By Institutions | 51.14 % | ||||
| Price To Book | 5.02 X | ||||
| Price To Sales | 3.17 X | ||||
| Revenue | 45.81 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 13.42 B | ||||
| Net Income | 6.9 B | ||||
| Total Debt | 28.62 B | ||||
| Book Value Per Share | 26.27 X | ||||
| Cash Flow From Operations | 10.35 B | ||||
| Earnings Per Share | 3.30 X | ||||
| Price To Earnings To Growth | 0.71 X | ||||
| Target Price | 13412.5 | ||||
| Number Of Employees | 89.9 K | ||||
| Beta | 0.18 | ||||
| Market Capitalization | 162.38 B | ||||
| Total Asset | 101.12 B | ||||
| Retained Earnings | 4.52 B | ||||
| Working Capital | (5.49 B) | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 101.12 B | ||||
| Last Dividend Paid | 2.97 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.